Gefitinib 250mg"'''"'

Gefitinib
GEFISTERIS 250   is a medication that belongs to a class of drugs known as tyrosine kinase inhibitors. It is primarily used in the treatment of non-small cell lung cancer (NSCLC), particularly in cases where the cancer cells have specific mutations in the epidermal growth factor receptor (EGFR) gene.
EGFR is a protein involved in cell growth and division. Certain mutations in the EGFR gene can lead to the overactivation of EGFR, promoting the growth of cancer cells. GEFISTERIS works by blocking the activity of EGFR, inhibiting the signaling pathways that contribute to cancer cell proliferation.
GEFISTERIS is typically prescribed for advanced or metastatic NSCLC that has not responded to other treatments or in cases where the specific EGFR mutations are present. It is not suitable for all patients with lung cancer, and genetic testing is often performed to identify the presence of EGFR mutations before initiating treatment.
It is important to note that GEFISTERIS is a prescription medication and should only be used under the guidance of a healthcare professional who has experience with its use. The dosage and duration of treatment will be determined by your healthcare provider based on your individual circumstances.
Common side effects of GEFISTERIS can include skin rash, diarrhea, nausea, vomiting, and changes in liver function tests. Some patients may also experience more severe side effects, such as interstitial lung disease or liver toxicity, although these are relatively rare.
If you are prescribed GEFISTERIS or have any concerns about its use, it is essential to discuss them with your healthcare provider. They can provide detailed information about the medication, its potential benefits, risks, and side effects, as well as monitor your progress during treatment.
For further information please contact:
info@sterispharma.com
Order Now - https://www.sterisonline.com/product/gefisteris-250-133658